Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Adenocarcinoma × apatinib × Clear all

Phase

Status

Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Peritoneal Metastases From Gastric Cancer 1 Ovarian Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Esophageal Squamous Cell Carcinoma 1 Epstein-Barr Virus Infections 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Gemcitabine 6 pembrolizumab 5 Carboplatin 5 Capecitabine 5 Pemetrexed 3 Oxaliplatin 3 Irinotecan 3 osimertinib 2 Sunitinib 2 Radiotherapy 2 Paclitaxel 2 Fluorouracil 2 130-nm albumin-bound paclitaxel 2 trifluridine tipiracil drug combination 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 sintilimab 1 seribantumab 1 selinexor 1 rubitecan 1 regorafenib 1 pralsetinib 1 olaparib 1 niraparib 1 linifanib 1 ixabepilone 1 ganitumab 1 eribulin 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407976 2020-07-15

APPEASE

University of Utah

Phase 1 Terminated

Adenocarcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡